Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Academy, Accelera, accelerate, acceleration, Achillion, Adlai, al, Allovectin, Amgen, Andrew, Aon, approach, Aranesp, arm, ascribed, basket, billed, biochemistry, Biogen, biopharma, blockade, blockbuster, bolstered, Brown, BSc, California, capturing, Celgene, Chartered, Chevalier, Chile, China, Chinese, constraining, core, CryptoMedicx, daily, Deborah, Diego, discovering, doctorate, economy, EMA, EMBO, EMD, Enbrel, Epogen, Fame, fellowship, fifteen, fiftieth, FluMist, founder, Gairdner, geopolitical, Governor, Guelph, Guttadauro, Halifax, Hall, hazard, Hewitt, Hong, hormone, Howlader, HR, Idec, Immunovaccine, Indian, inducted, influenza, inhaled, input, INSEAD, instability, Intriguingly, Ivey, Jamieson, Journal, Kellogg, Kong, Korea, laid, launch, Lupron, Macau, MAP, mbc, median, MedImmune, Merck, metabolic, Michigan, Military, mOS, Nadia, Neuroimmunology, NJ, noncurrent, Northwestern, Nortye, occurrence, OS, parallel, partial, PCAOB, PharmaTech, pipeline, Plant, PLC, political, predominant, premium, prepaid, Prevacid, prevalence, Princeton, programme, PSU, Quest, Radford, radioimmunotherapy, ratio, recognised, recognising, redacted, regional, regualtory, resolved, Serono, Shantha, Singapore, South, SPCA, specialty, stable, subgroup, subtype, Taiwan, TAP, tenure, terrorism, traditional, trainee, underwritten, uneven, upfront, Vaccibody, Vical, war, West, whichever, Zevalin
Removed:
AstraZeneca, author, book, Bray, CancerBase, chemistry, Cincinnati, Dean, Dickinson, Dikshit, Dinning, DM, Epilepsy, Ervik, Eser, Ferlay, forecast, Forman, globocan, iarc, ICI, Ligand, lung, Lyon, Manhattan, MHRA, mortality, Mt, Neurology, Parkin, Pennsylvania, Philadelphia, privately, professor, Rebelo, Residency, resignation, Roche, Schultz, Sinai, Soerjomataram, Southern, stating, thirty, VaxInnate, VP, women, Xmark
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 4.43 Exhibit 4.43
- 4.44 Exhibit 4.44
- 4.45 Exhibit 4.45
- 4.46 Exhibit 4.46
- 4.47 Exhibit 4.47
- 4.48 Exhibit 4.48
- 8.0 Exhibit 8.0
- 12.1 Exhibit 12.1
- 12.2 Exhibit 12.2
- 13.1 Exhibit 13.1
- 13.2 Exhibit 13.2
- 15.1 Exhibit 15.1
- 15.2 Exhibit 15.2
- Download Excel data file
- View Excel data file
ONCY similar filings
Filing view
External links
EXHIBIT 13.1
CERTIFICATION PURSUANT TO
18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Oncolytics Biotech Inc. (the “Company”) on Form 20-F for the fiscal year ended December 31, 2017 as filed with the Securities and Exchange Commission on the date here of (the “Report”), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Matthew Coffey
_________________________________
Matthew Coffey, PhD
Chief Executive Officer
Principal Executive Officer
March 19, 2018
A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.